Своевременное начало инсулинотерапии при сахарном диабете типа 2: патогенетическое и клиническое обоснование

1. Joslin EP. Proceedings for the 19th annual meeting Of the American Society for Clinical Investigation, Atlantic City, New Jersey, USA. J Clin Invest 1927; 4: 435–6.
2. Festa A, Williams K, D’Agostino R Jr et al. The natural course of beta-cell function in nondia-betic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes 2006; 55: 1114–20.
3. Fonseca VA. Defining and characterizing the progression of type 2 diabetes. Diabetes Care 2009; 32 (Suppl. 2): 151–6.
4. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44 (11): 1249–58.
5. Wallace TM, Matthews DR. Coefficient of failure: a methodology for examining longitudinal beta-cell function in Type 2 diabetes. Diabet Med 2002; 19 (6): 465–9.
6. RC Turner, ST McCarthy, RR Holman et al. Beta-cell function improved by supplementing basal insulin secretion in mild diabetes. Br Med J 1976; 1: 1252–54.
7. Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care 2004; 
27 (5): 1028–32.
8. Li Y, Xu W, Liao Z et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care 2004; 27 (11): 2597–602.
9. Weng J, Li Y, Xu W et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet 2008; 371 (9626): 1753–60.
10. Chen HS, Wu TE, Jap TS et al. Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy. Diabetes Care 2008; 31 (10): 1927–32. Epub 2008 Jun 12.
11. American Association of Clinical Endocrinology Guidelines for management Type 2 Diabetes www.aace.com.
12. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И.Дедова, М.В.Шестаковой. 5-й выпуск. М., 2011.
13. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004; 27 (7): 1535–40.
14. Esposito K, Chiodini P, Bellastella G et al. Proportion of patients at HbA1c target < 7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials with 78 945 patients. Diabetes Obes Metab 2012; 14 (3): 228–33. 
15. Janka HU, Plewe G, Riddle MC et al. Comparison of basal insulin added to oral agents vs twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005; 28: 254–9.
16. Bretzel RG, Nuber U, Landgraf W et al. Once-daily basal insulin glargine vs thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycae- mic agents (APOLLO): an open randomised controlled trial. Lancet 2008; 371: 1073–84.
17. Holman RR, Farmer AJ, Davies MJ et al; 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009; 361 (18): 1736–47. Epub 2009 Oct 22.
18. Шестакова М.В. Программа A1chieve в России: многоцентровое проспективное наблюдательное исследование эффективности и безопасности начала и интенсификации инсулинотерапии с помощью аналогов инсулина у пациентов с сахарным диабетом 2 типа, ранее не получавших инсулин, в повседневной клинической практике. Сахарный диабет. 2012; 1: 63–70.
19. Inzucchi SE, Bergenstal RM, Buse JB et al Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35 (6): 1364–79. Epub 2012 Apr 19.
20. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care 2003; 26: 3080–6.
21. Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M et al Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442–51.
22. Davies M, Storms F, Shutler S et al. AT.LANTUS study group. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005; 28: 1282–8. 
23. Home PD, Fritsche A, Schinzel S et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010; 12 (9): 772–9.
24. Шестакова М.В. Реальная клиническая практика лечения сахарного диабета 2 типа в Российской Федерации по данным открытой проспективной наблюдательной программы «ДИА-КОНТРОЛЬ». Сахарный диабет. 2011; 4: 75–80.
25. Casciano R, Malangone E, Ramachandran A et al. A quantitative assessment of patient barriers to insulin. Int J Clin Pract 2011; 65 (4): 408–14.
26. Rosenstock J et al. 555-P ADA 66th Annual Scientific Sessions, Washington, DC, June 2006.
27. Fonseca V, Gill J, Zhou R et al. An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia. Diabetes Obes Metab 2011; 13 (9): 814–22. 
28. Pennartz C, Schenker N, Menge BA et al. Chronic reduction of fasting glycemia with insulin glargine improves first- and second-phase insulin secretion in patients with type 2 diabetes. Diabetes Care 2011; 34 (9): 2048–53. Epub 2011 Jul 20.
29. ORIGIN Trial Investigators, Gerstein HC, Bosch J, Dagenais GR et al. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012; 367 (4): 319–28. Epub 2012 Jun 11.
30. Colhoun HM. On behalf of the SDRN Epidemiology Group Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52: 1755–65.
31. Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52: 1766–77.
32. Hemkens LG, Grouven U, Bender R et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52: 1732–44.
33. Jonasson JM, Ljung R, Talbäck M et al. Insulin glargine use and short-term incidence of malignancies – a population-based follow-up study in Sweden. Diabetologia 2009; 52: 1745–54.

И.В.Глинкина  

Кафедра эндокринологии лечебного факультета ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ